MAPT and Alzheimer disease: Alzheimer’s disease (AD) is a debilitating neurodegenerative disease characterized among others, by the progressive accumulation of β-amyloid 1-42 (Aβ42) and tau protein aggregates, widespread transcriptional changes throughout the brain, and ultimately, profound cognitive deficits [1–3].